CASAC Pharmacology and Medication-Assisted Treatment 2 — Questions and Answers

Question 1: What is the mechanism by which naloxone (Narcan) reverses an opioid overdose?

It metabolizes the opioid in the bloodstream
It competitively displaces opioids from mu-opioid receptors, rapidly reversing respiratory depression without producing any opioid effects of its own (Correct answer)
It stimulates the heart to counteract the opioid's effects
It increases the body's natural endorphin production

Correct answer: It competitively displaces opioids from mu-opioid receptors, rapidly reversing respiratory depression without producing any opioid effects of its own

Naloxone is a competitive opioid antagonist that binds to mu-opioid receptors with higher affinity than most opioids, rapidly displacing them and reversing respiratory depression.

Naloxone is a pure competitive antagonist at mu-opioid receptors. It has a higher binding affinity than most opioids (morphine, heroin, oxycodone), meaning it can displace them from receptors even when the receptors are already occupied. Upon binding, naloxone produces no opioid effects (no analgesia, no euphoria, no respiratory depression) — it simply blocks the receptor. This competitive displacement rapidly reverses the life-threatening respiratory depression caused by opioid overdose. Critical clinical considerations: (1) Naloxone's half-life (30-90 minutes) is shorter than most opioids, meaning overdose symptoms can return (renarcotization) requiring repeat doses; (2) In opioid-dependent individuals, naloxone will precipitate acute withdrawal (which is uncomfortable but not life-threatening — this is far preferable to death from overdose); (3) Available as intranasal spray (Narcan) and injectable formulation; (4) Some synthetic opioids (fentanyl, carfentanil) may require multiple doses due to their extreme potency; (5) Naloxone is increasingly available without prescription as a harm reduction measure.

Question 2: Which medication used in the treatment of alcohol use disorder reduces drinking by modulating the opioid system to decrease the rewarding effects of alcohol?

Disulfiram
Naltrexone (Correct answer)
Acamprosate
Topiramate

Correct answer: Naltrexone

Naltrexone reduces alcohol's rewarding effects by blocking mu-opioid receptors, which mediate part of alcohol's pleasurable reinforcement through endogenous opioid release.

Naltrexone is FDA-approved for both opioid use disorder and alcohol use disorder, working through opioid receptor blockade. Alcohol consumption triggers the release of endogenous opioids (endorphins and enkephalins), which contribute to the subjective rewarding effects of drinking, particularly the 'high' or euphoria. By blocking mu-opioid receptors, naltrexone attenuates this reward signal, making drinking less pleasurable and reducing the positive reinforcement that maintains the drinking behavior. The clinical result is: reduced heavy drinking days, fewer drinks per drinking occasion, and for some patients, achievement of abstinence. Naltrexone is available as daily oral tablets (50mg) and as a monthly extended-release intramuscular injection (Vivitrol, 380mg). The injectable formulation addresses adherence challenges. Unlike disulfiram (which creates aversive reactions) and acamprosate (which addresses glutamate-mediated protracted withdrawal), naltrexone specifically targets the reward pathway. It does not cause aversive reactions if alcohol is consumed — rather, drinking becomes less rewarding.

Question 3: A client prescribed buprenorphine/naloxone (Suboxone) asks why naloxone is included in the formulation. What is the correct explanation?

Naloxone is the active ingredient that treats the addiction
Naloxone is included as an abuse deterrent — it is poorly absorbed sublingually (the intended route) but if the medication is injected, naloxone becomes active and precipitates withdrawal, discouraging misuse (Correct answer)
Naloxone enhances the effects of buprenorphine
Naloxone is included to treat potential allergic reactions

Correct answer: Naloxone is included as an abuse deterrent — it is poorly absorbed sublingually (the intended route) but if the medication is injected, naloxone becomes active and precipitates withdrawal, discouraging misuse

Naloxone is added as a tamper-resistant measure: when taken sublingually as directed, naloxone has minimal effect, but if injected, it precipitates withdrawal, deterring intravenous misuse.

The combination of buprenorphine and naloxone (marketed as Suboxone) is a carefully designed formulation. Buprenorphine is a partial mu-opioid agonist that is the therapeutic component — it reduces cravings, prevents withdrawal, and blocks the effects of other opioids. When taken as directed (sublingually or buccally), the buprenorphine is well absorbed through the oral mucosa, while naloxone has very poor sublingual bioavailability (approximately 3-5%) and is largely inactive. However, if someone attempts to misuse the medication by dissolving and injecting it, the naloxone becomes fully bioavailable intravenously and, being an opioid antagonist, will precipitate acute opioid withdrawal — an extremely unpleasant experience that strongly deters repeated injection. This abuse-deterrent design allows buprenorphine to be prescribed in office-based settings (rather than requiring daily observed dosing in an OTP). Buprenorphine-only formulations (Subutex) exist for specific clinical situations (pregnancy, documented naloxone allergy) where the combination product is not appropriate.

Question 4: What is the rationale for using methadone maintenance treatment (MMT) rather than medically supervised withdrawal alone for opioid use disorder?

Methadone maintenance is cheaper than withdrawal management
Research consistently shows that maintenance treatment produces better long-term outcomes than withdrawal alone, including reduced illicit drug use, reduced overdose deaths, reduced criminal activity, and improved retention in treatment (Correct answer)
There is no clinical rationale; withdrawal alone is always preferable
Methadone maintenance is only used for patients who refuse other treatments

Correct answer: Research consistently shows that maintenance treatment produces better long-term outcomes than withdrawal alone, including reduced illicit drug use, reduced overdose deaths, reduced criminal activity, and improved retention in treatment

Evidence overwhelmingly supports maintenance treatment over withdrawal-only approaches, with maintenance producing significantly better outcomes across multiple domains.

The evidence supporting methadone maintenance treatment (MMT) over withdrawal-only approaches (detoxification) is among the strongest in all of addiction medicine. Research spanning over 50 years demonstrates that MMT: (1) Reduces illicit opioid use by 60-80% compared to withdrawal-only or no treatment; (2) Reduces overdose mortality — patients in MMT have one-third to one-quarter the mortality rate of untreated opioid users; (3) Reduces criminal activity and incarceration; (4) Reduces HIV and hepatitis transmission through decreased injection drug use; (5) Improves social functioning, employment, and family relationships; (6) Has far superior treatment retention rates — detoxification alone has relapse rates exceeding 90% within one year. The rationale is grounded in the understanding of opioid addiction as a chronic brain disorder: the neurobiological changes persist long after withdrawal is complete, and simply removing the substance without maintaining neurochemical stability leaves patients vulnerable to relapse. MMT provides a stable, long-acting opioid that normalizes brain function, eliminates withdrawal, reduces cravings, and blocks the effects of other opioids, creating a foundation for psychosocial rehabilitation.

Question 5: Which of the following is a significant pharmacological concern when prescribing medications for substance use disorders in a client who is pregnant?

Pregnant clients should never receive any medication for SUD
Medication selection must weigh the risks of the medication against the risks of untreated addiction, with specific considerations including teratogenicity, neonatal withdrawal, and breastfeeding compatibility (Correct answer)
Pregnancy has no effect on medication decisions for SUD
Only herbal supplements should be used during pregnancy

Correct answer: Medication selection must weigh the risks of the medication against the risks of untreated addiction, with specific considerations including teratogenicity, neonatal withdrawal, and breastfeeding compatibility

Medication decisions in pregnant clients with SUD require careful risk-benefit analysis considering teratogenicity, neonatal effects, and the significant risks of untreated addiction to both mother and fetus.

Treating substance use disorders in pregnancy requires nuanced pharmacological decision-making that considers risks to both mother and developing fetus. Key considerations include: (1) For opioid use disorder, medication-assisted treatment (methadone or buprenorphine) is the standard of care — NOT detoxification, as withdrawal can cause fetal distress and miscarriage. Neonatal opioid withdrawal syndrome (NOWS, formerly NAS) is expected and manageable. Buprenorphine monotherapy (without naloxone) is preferred in pregnancy; (2) For alcohol use disorder, neither naltrexone, acamprosate, nor disulfiram is recommended during pregnancy due to insufficient safety data or known risks. The focus shifts to psychosocial interventions; (3) For nicotine use disorder, nicotine replacement therapy may be considered when behavioral approaches are insufficient; (4) Untreated substance use during pregnancy carries serious risks including preterm birth, low birth weight, placental abruption, fetal alcohol spectrum disorders, and neonatal drug toxicity. The risk-benefit analysis recognizes that in many cases, medication-assisted treatment, despite potential neonatal effects, produces better outcomes for both mother and baby than untreated addiction.

Question 6: What pharmacological class does gabapentin belong to, and why is it increasingly used (off-label) in substance abuse treatment?

It is an opioid used for pain management only
It is an anticonvulsant/neuropathic pain medication used off-label for alcohol use disorder because it reduces anxiety, insomnia, and cravings while having a generally favorable safety profile compared to benzodiazepines (Correct answer)
It is a benzodiazepine used for anxiety
It is an antidepressant used for depression during recovery

Correct answer: It is an anticonvulsant/neuropathic pain medication used off-label for alcohol use disorder because it reduces anxiety, insomnia, and cravings while having a generally favorable safety profile compared to benzodiazepines

Gabapentin is an anticonvulsant increasingly used off-label in substance abuse treatment for its effects on anxiety, sleep, and cravings, with lower addiction risk than benzodiazepines.

Gabapentin is classified as an anticonvulsant (anti-epileptic) that also has FDA approval for neuropathic pain. Its mechanism involves modulation of voltage-gated calcium channels and potentially GABA-related pathways (though it does not directly bind to GABA receptors). In substance abuse treatment, gabapentin has gained attention for several off-label applications: (1) Alcohol use disorder — clinical trials show it reduces heavy drinking, promotes abstinence, and is particularly effective for patients with high levels of alcohol withdrawal symptoms. It addresses anxiety, insomnia, and dysphoria that commonly trigger relapse; (2) Alcohol withdrawal management — used as an adjunct or alternative to benzodiazepines for mild-to-moderate withdrawal; (3) Cannabis use disorder — some evidence for reducing withdrawal symptoms; (4) Co-occurring anxiety and insomnia — common in early recovery. The advantage over benzodiazepines is a generally lower abuse potential and no cross-tolerance with alcohol. However, gabapentin misuse has been increasingly reported, particularly in combination with opioids, leading some states to classify it as a controlled substance. Clinicians should monitor for misuse while recognizing its therapeutic utility.

CASAC Pharmacology and Medication-Assisted Treatment 2

What is the mechanism by which naloxone (Narcan) reverses an opioid overdose?